<DOC>
	<DOCNO>NCT02413580</DOCNO>
	<brief_summary>This multicenter , prospective , open-label , non-controlled study ass efficacy safety IV dose 2 g/kg IGIV-C subject MG exacerbation .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety IGIV-C Patients With Myasthenia Gravis Exacerbations</brief_title>
	<detailed_description>The study consist single dose course IGIV-C treatment follow 28-days post-infusion assessment . The total duration study participation subject 28 ± 2 day . Approximately 50 subject , age 18 great , plan enrol study receive single , total dose 2 g/kg IGIV-C 2 consecutive day ( dose 1 g/kg per day ) across multiple center Argentina , Canada , Europe South Africa .</detailed_description>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Subjects must willing able provide write informed consent ( applicable , legally authorize representative may provide informed consent behalf subject ) . Subjects meet clinical criterion diagnosis MG exacerbation define worsen MG symptom define Myasthenia Gravis Foundation America ( MGFA ) classification IVb V. Subjects longterm ( 8 week ) corticosteroid treatment MG . Female subject childbearing potential must negative test pregnancy ( human chorionic gonadotropin [ HCGbased assay ] ) . Subjects must willing comply aspect clinical trial protocol , include blood sample longterm storage extra sample , entire duration study . Subjects receive immune globulin treatment give IV , subcutaneous intramuscular route within last 30 day . Subjects documentation lack clinical response intravenous immunoglobulin ( IVIg ) therapy MG . Subjects document positive antibody direct MuSK . Subjects corticosteroid ( CS ) treatment initiate within last 8 week modify within last 2 week . Subjects plasma exchange ( PLEX ) within last 30 day . Subjects MG exacerbation attributable change medication infection evident infection define , limited , presence least one follow diagnostic feature : 1 ) axillary temperature ≥38°C , 2 ) positive blood culture infective microorganism , 3 ) white blood cell count &gt; 12×10^9/L differential white blood cell count &gt; 10 % band neutrophil ( &gt; 1.2×10^9/L ) , 4 ) pulmonary infiltrate consolidation chest Xray . Alternatively , sign symptom may consider diagnosis evident infection accord Investigator 's judgement . Subjects inadequate venous access . Subjects history anaphylactic reaction severe reaction bloodderived product . Subjects history intolerance component investigational product . Subjects document diagnosis thrombotic complication polyclonal IVIG therapy past . Subjects history recent ( within last year ) myocardial infarction , stroke uncontrolled hypertension . Subjects suffer uncontrolled congestive heart failure , embolism document electrocardiogram ( ECG ) change indicative myocardial ischemia atrial fibrillation . Subjects current know hyperviscosity hypercoagulable state . Subjects currently receive anticoagulation therapy . Subjects history chronic alcoholism illicit drug abuse ( addiction ) 12 month precede Baseline Visit . Subjects currently receive , receive within 3 month prior Baseline Visit , investigational medicinal product device . Subjects know Immunoglobulin A ( IgA ) deficiency antiIgA serum antibody . Subjects renal impairment ( i.e. , serum creatinine exceed 1.5 time upper limit normal [ ULN ] expect normal range test laboratory ) . Subjects aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level exceed 2.5 time ULN expect normal range test laboratory . Subjects haemoglobin level &lt; 9 g/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>